Status:
UNKNOWN
Administration for Placebo Group and Evalution the Safety and Efficacy in Atopic Dermatitis Patients
Lead Sponsor:
Kang Stem Biotech Co., Ltd.
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
Brief Summary
A Multi-center, Open, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of FURESTEM-AD inj. in Patients with Moderate to Severe Chronic Atopic Dermatitis Who Participated in a Placebo Grou...
Eligibility Criteria
Inclusion
- Subject who enrolled K0102 Clinical Trial(parent study) and be assigned to a placebo group
- Subjects who understand and voluntarily sign an informed consent form
Exclusion
- Subjects with medical history or surgery/procedure history
- Subjects with diseases at the time of participation in this study (systemic infection, other serious skin disorders, pigmentation or extensive scarring in atopic dermatitis symptom region)
- Pregnant, breast-feeding women or women who plan to become pregnant during six months after administering the clinical trial medication
- Subjects who participate in other clinical trial or participated in other clinical trial within 4 weeks
- In case follow-up is not possible to end of this study period
- Any other condition which the investigator judges would make patient unsuitable for study participation
Key Trial Info
Start Date :
August 29 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT04087863
Start Date
August 29 2019
End Date
December 31 2024
Last Update
September 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, South Korea, 06591